---
title: "Key facts: ChrysCapital acquires stake in Novartis India; Remibrutinib trials positive; US expansion planned"
description: "ChrysCapital has secured a majority stake in Novartis India, including standard warranties and a commitment to support the mandatory open offer to public shareholders as per SEBI rules.1Novartis AG an"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276499806.md"
published_at: "2026-02-21T02:03:07.000Z"
---

# Key facts: ChrysCapital acquires stake in Novartis India; Remibrutinib trials positive; US expansion planned

> ChrysCapital has secured a majority stake in Novartis India, including standard warranties and a commitment to support the mandatory open offer to public shareholders as per SEBI rules.1Novartis AG announced positive results from a phase 3 trial of Remibrutinib for chronic inducible urticaria, showing higher response rates than placebo at Week 12, meeting primary endpoints.2Novartis is expanding in the US with new manufacturing and research facilities in North Carolina and California, plus a radioligand therapy site in Florida, following a major investment.3

-   ChrysCapital has secured a majority stake in Novartis India, including standard warranties and a commitment to support the mandatory open offer to public shareholders as per SEBI rules.1
-   Novartis AG announced positive results from a phase 3 trial of Remibrutinib for chronic inducible urticaria, showing higher response rates than placebo at Week 12, meeting primary endpoints.2
-   Novartis is expanding in the US with new manufacturing and research facilities in North Carolina and California, plus a radioligand therapy site in Florida, following a major investment.3

### Related Stocks

- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [NDIA.US - Global X India Active ETF](https://longbridge.com/en/quote/NDIA.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [NOT.DE - Novartis AG](https://longbridge.com/en/quote/NOT.DE.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [NVS.US - NOVARTIS AG](https://longbridge.com/en/quote/NVS.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Novartis’ RemIND trial of oral remibrutinib meets primary endpoint | Novartis announced that its Phase III RemIND trial for oral remibrutinib in chronic inducible urticaria (CIndU) met its  | [Link](https://longbridge.com/en/news/276335557.md) |
| Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU) | Novartis announced positive results from its Phase III RemIND trial for remibrutinib, a selective oral BTK inhibitor, in | [Link](https://longbridge.com/en/news/276201069.md) |
| -Novartis to exit Indian unit in $159 million deal | Swiss drugmaker Novartis is selling its 70.68% stake in its Indian unit for 14.46 billion rupees ($159 million) to a con | [Link](https://longbridge.com/en/news/276407932.md) |
| Novartis Reports Positive Results from Phase 3 Trial of Chronic Inducible Urticaria Oral Drug | Novartis Reports Positive Results from Phase 3 Trial of Chronic Inducible Urticaria Oral Drug | [Link](https://longbridge.com/en/news/276202963.md) |
| Novartis reports final data of ALIGN trial in IgAN | Novartis has reported final data from the Phase III ALIGN trial, demonstrating that Vanrafia (atrasentan) significantly  | [Link](https://longbridge.com/en/news/276055699.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.